Tetra Bio-Pharma Gets First Order of Cannabis Inhalation Device

Tetra Bio-Pharma (TSXV:TBP; OTCQB:TBPMF) announced the first official sale of its Rx Princeps inhalation device.
As quoted in the press release:

“I am happy to announce the first batch order of our medical cannabis inhalation devices. This is the first step in generating a steady revenue stream and it is the beginning of a new phase in our development. Sales of Rx Princeps inhalation device will be an additional revenue stream for Tetra. Our inhalation device is a unique, high quality, CSA-approved customized titanium pipe, designed by our partner, Ford Pharmacy. With this launch Tetra is providing a high quality, standardized treatment with clinical data to patients in need.” As Rx Princeps (dried cannabis) will soon be launched under ACMPR through Aphria, and we are expecting to generate around $1.5 millions in sales, in fiscal 2018. Through our promotion and education efforts in Quebec, New Brunswick and part of Ontario, we estimate that over eight thousand patients will start using Rx Princeps under prescription from their doctors over in the next twelve months.” states Bernard Fortier, CEO of Tetra.

Click here to read the full press release.

Source: www.marketwired.com